Cite
Raghavan K, Dedeepiya VD, Suryaprakash V, et al. Beneficial effects of novel aureobasidium pullulans strains produced beta-1,3-1,6 glucans on interleukin-6 and D-dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study. Biomed Pharmacother. 2021;112243doi: 10.1016/j.biopha.2021.112243.
Raghavan, K., Dedeepiya, V. D., Suryaprakash, V., Rao, K. S., Ikewaki, N., Sonoda, T., Levy, G. A., Iwasaki, M., Senthilkumar, R., Preethy, S., & Abraham, S. J. (2021). Beneficial effects of novel aureobasidium pullulans strains produced beta-1,3-1,6 glucans on interleukin-6 and D-dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 112243. https://doi.org/10.1016/j.biopha.2021.112243
Raghavan, Kadalraja, et al. "Beneficial effects of novel aureobasidium pullulans strains produced beta-1,3-1,6 glucans on interleukin-6 and D-dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. (2021): 112243. doi: https://doi.org/10.1016/j.biopha.2021.112243
Raghavan K, Dedeepiya VD, Suryaprakash V, Rao KS, Ikewaki N, Sonoda T, Levy GA, Iwasaki M, Senthilkumar R, Preethy S, Abraham SJ. Beneficial effects of novel aureobasidium pullulans strains produced beta-1,3-1,6 glucans on interleukin-6 and D-dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study. Biomed Pharmacother. 2021 Sep 25;112243. doi: 10.1016/j.biopha.2021.112243. Epub 2021 Sep 25. PMID: 34840031; PMCID: PMC8463314.
Copy
Download .nbib